Survivorship after neoadjuvant chemotherapy

Affiliations

¹ Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
² Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address: niuwenquan_shcn@163.com.

Comment

Jin Zhang et al. Lancet Oncol. 2022 Mar.

. 2022 Mar;23(3):e95.

doi: 10.1016/S1470-2045(22)00011-0.

¹ Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
² Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address: niuwenquan_shcn@163.com.

No abstract available

Conflict of interest statement

We declare no competing interests.

Survivorship after neoadjuvant chemotherapy - Authors' reply.
Yau C, Osdoit M, Esserman LJ, Symmans WF. Yau C, et al. Lancet Oncol. 2022 Mar;23(3):e96. doi: 10.1016/S1470-2045(22)00085-7. Lancet Oncol. 2022. PMID: 35240097 No abstract available.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Yau C, et al. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902335 Free PMC article.